nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—FOLR1—bone cancer	0.256	0.71	CbGaD
Methotrexate—breast cancer—bone cancer	0.12	0.315	CtDrD
Methotrexate—DHFR—bone cancer	0.105	0.29	CbGaD
Methotrexate—muscle cancer—bone cancer	0.0965	0.253	CtDrD
Methotrexate—germ cell cancer—bone cancer	0.0867	0.228	CtDrD
Methotrexate—lung cancer—bone cancer	0.0779	0.204	CtDrD
Methotrexate—ABCC10—Doxorubicin—bone cancer	0.0253	0.161	CbGbCtD
Methotrexate—ABCC3—Cisplatin—bone cancer	0.0237	0.151	CbGbCtD
Methotrexate—ABCC1—Epirubicin—bone cancer	0.0184	0.117	CbGbCtD
Methotrexate—ABCC3—Doxorubicin—bone cancer	0.0159	0.101	CbGbCtD
Methotrexate—ABCC2—Carboplatin—bone cancer	0.0126	0.0803	CbGbCtD
Methotrexate—ABCG2—Carboplatin—bone cancer	0.0114	0.0726	CbGbCtD
Methotrexate—ABCC2—Cisplatin—bone cancer	0.0108	0.0686	CbGbCtD
Methotrexate—ABCC1—Doxorubicin—bone cancer	0.00977	0.0621	CbGbCtD
Methotrexate—ABCG2—Cisplatin—bone cancer	0.00975	0.062	CbGbCtD
Methotrexate—ABCC2—Doxorubicin—bone cancer	0.00723	0.046	CbGbCtD
Methotrexate—ABCG2—Doxorubicin—bone cancer	0.00654	0.0416	CbGbCtD
Methotrexate—ABCB1—Cisplatin—bone cancer	0.00352	0.0224	CbGbCtD
Methotrexate—ATIC—pes—bone cancer	0.00253	0.195	CbGeAlD
Methotrexate—ABCB1—Doxorubicin—bone cancer	0.00236	0.015	CbGbCtD
Methotrexate—ATIC—leg—bone cancer	0.00129	0.0993	CbGeAlD
Methotrexate—ATIC—forelimb—bone cancer	0.00128	0.0986	CbGeAlD
Methotrexate—Pralatrexate—DHFR—bone cancer	0.00119	0.556	CrCbGaD
Methotrexate—ATIC—hindlimb—bone cancer	0.00115	0.0887	CbGeAlD
Methotrexate—ATIC—appendage—bone cancer	0.000988	0.0761	CbGeAlD
Methotrexate—Pemetrexed—DHFR—bone cancer	0.000953	0.444	CrCbGaD
Methotrexate—FPGS—connective tissue—bone cancer	0.000292	0.0225	CbGeAlD
Methotrexate—ATIC—connective tissue—bone cancer	0.000282	0.0217	CbGeAlD
Methotrexate—SLC46A1—tendon—bone cancer	0.000232	0.0178	CbGeAlD
Methotrexate—GGH—tendon—bone cancer	0.000228	0.0176	CbGeAlD
Methotrexate—SLC46A1—spinal cord—bone cancer	0.000224	0.0172	CbGeAlD
Methotrexate—GGH—bone marrow—bone cancer	0.000221	0.017	CbGeAlD
Methotrexate—GGH—spinal cord—bone cancer	0.00022	0.0169	CbGeAlD
Methotrexate—FPGS—tendon—bone cancer	0.0002	0.0154	CbGeAlD
Methotrexate—SLCO4C1—bone marrow—bone cancer	0.000196	0.0151	CbGeAlD
Methotrexate—FPGS—spinal cord—bone cancer	0.000193	0.0149	CbGeAlD
Methotrexate—TYMS—connective tissue—bone cancer	0.000191	0.0147	CbGeAlD
Methotrexate—DHFR—connective tissue—bone cancer	0.000189	0.0146	CbGeAlD
Methotrexate—ATIC—spinal cord—bone cancer	0.000187	0.0144	CbGeAlD
Methotrexate—PGD—connective tissue—bone cancer	0.000182	0.014	CbGeAlD
Methotrexate—SLCO1C1—spinal cord—bone cancer	0.000155	0.012	CbGeAlD
Methotrexate—SLCO3A1—tendon—bone cancer	0.000142	0.0109	CbGeAlD
Methotrexate—SLCO3A1—spinal cord—bone cancer	0.000137	0.0105	CbGeAlD
Methotrexate—TYMS—tendon—bone cancer	0.000132	0.0101	CbGeAlD
Methotrexate—DHFR—tendon—bone cancer	0.00013	0.01	CbGeAlD
Methotrexate—TYMS—bone marrow—bone cancer	0.000127	0.00981	CbGeAlD
Methotrexate—DHFR—bone marrow—bone cancer	0.000126	0.00971	CbGeAlD
Methotrexate—DHFR—spinal cord—bone cancer	0.000126	0.00967	CbGeAlD
Methotrexate—PGD—tendon—bone cancer	0.000125	0.00964	CbGeAlD
Methotrexate—PGD—bone marrow—bone cancer	0.000121	0.00934	CbGeAlD
Methotrexate—PGD—spinal cord—bone cancer	0.000121	0.0093	CbGeAlD
Methotrexate—SLC16A1—tendon—bone cancer	0.000117	0.009	CbGeAlD
Methotrexate—SLC16A1—spinal cord—bone cancer	0.000113	0.00868	CbGeAlD
Methotrexate—AOX1—tendon—bone cancer	0.00011	0.00849	CbGeAlD
Methotrexate—ABCC10—tendon—bone cancer	0.000107	0.00827	CbGeAlD
Methotrexate—ABCC10—bone marrow—bone cancer	0.000104	0.00801	CbGeAlD
Methotrexate—ABCC10—spinal cord—bone cancer	0.000104	0.00797	CbGeAlD
Methotrexate—SLCO1A2—spinal cord—bone cancer	8.92e-05	0.00687	CbGeAlD
Methotrexate—ABCC4—tendon—bone cancer	8.9e-05	0.00686	CbGeAlD
Methotrexate—ABCC4—bone marrow—bone cancer	8.62e-05	0.00664	CbGeAlD
Methotrexate—ABCC2—tendon—bone cancer	8.62e-05	0.00664	CbGeAlD
Methotrexate—ABCC1—tendon—bone cancer	7.59e-05	0.00585	CbGeAlD
Methotrexate—Malnutrition—Cisplatin—bone cancer	7.33e-05	0.00156	CcSEcCtD
Methotrexate—Lymphadenopathy—Epirubicin—bone cancer	7.33e-05	0.00156	CcSEcCtD
Methotrexate—Coma—Doxorubicin—bone cancer	7.28e-05	0.00155	CcSEcCtD
Methotrexate—Thrombophlebitis—Epirubicin—bone cancer	7.22e-05	0.00154	CcSEcCtD
Methotrexate—Ecchymosis—Doxorubicin—bone cancer	7.2e-05	0.00153	CcSEcCtD
Methotrexate—Neoplasm—Doxorubicin—bone cancer	7.2e-05	0.00153	CcSEcCtD
Methotrexate—Mouth ulceration—Doxorubicin—bone cancer	7.2e-05	0.00153	CcSEcCtD
Methotrexate—Bladder pain—Doxorubicin—bone cancer	7.2e-05	0.00153	CcSEcCtD
Methotrexate—Diabetes mellitus—Epirubicin—bone cancer	7.19e-05	0.00153	CcSEcCtD
Methotrexate—Photosensitivity—Epirubicin—bone cancer	7.12e-05	0.00151	CcSEcCtD
Methotrexate—Pulmonary oedema—Doxorubicin—bone cancer	7.09e-05	0.00151	CcSEcCtD
Methotrexate—Hepatic failure—Epirubicin—bone cancer	6.96e-05	0.00148	CcSEcCtD
Methotrexate—Sepsis—Doxorubicin—bone cancer	6.91e-05	0.00147	CcSEcCtD
Methotrexate—Vision blurred—Cisplatin—bone cancer	6.91e-05	0.00147	CcSEcCtD
Methotrexate—Ill-defined disorder—Cisplatin—bone cancer	6.8e-05	0.00145	CcSEcCtD
Methotrexate—Lymphadenopathy—Doxorubicin—bone cancer	6.78e-05	0.00144	CcSEcCtD
Methotrexate—Anaemia—Cisplatin—bone cancer	6.77e-05	0.00144	CcSEcCtD
Methotrexate—Renal failure acute—Epirubicin—bone cancer	6.77e-05	0.00144	CcSEcCtD
Methotrexate—Thrombophlebitis—Doxorubicin—bone cancer	6.68e-05	0.00142	CcSEcCtD
Methotrexate—Diabetes mellitus—Doxorubicin—bone cancer	6.65e-05	0.00141	CcSEcCtD
Methotrexate—Dermatitis exfoliative—Epirubicin—bone cancer	6.62e-05	0.00141	CcSEcCtD
Methotrexate—Malaise—Cisplatin—bone cancer	6.61e-05	0.00141	CcSEcCtD
Methotrexate—Photosensitivity—Doxorubicin—bone cancer	6.59e-05	0.0014	CcSEcCtD
Methotrexate—Leukopenia—Cisplatin—bone cancer	6.56e-05	0.0014	CcSEcCtD
Methotrexate—Anaphylactoid reaction—Epirubicin—bone cancer	6.46e-05	0.00137	CcSEcCtD
Methotrexate—Hepatic failure—Doxorubicin—bone cancer	6.44e-05	0.00137	CcSEcCtD
Methotrexate—Lethargy—Epirubicin—bone cancer	6.38e-05	0.00136	CcSEcCtD
Methotrexate—Cerebrovascular accident—Epirubicin—bone cancer	6.38e-05	0.00136	CcSEcCtD
Methotrexate—Convulsion—Cisplatin—bone cancer	6.35e-05	0.00135	CcSEcCtD
Methotrexate—Renal failure acute—Doxorubicin—bone cancer	6.26e-05	0.00133	CcSEcCtD
Methotrexate—Osteoarthritis—Epirubicin—bone cancer	6.25e-05	0.00133	CcSEcCtD
Methotrexate—Myalgia—Cisplatin—bone cancer	6.24e-05	0.00133	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	6.2e-05	0.00132	CcSEcCtD
Methotrexate—Discomfort—Cisplatin—bone cancer	6.17e-05	0.00131	CcSEcCtD
Methotrexate—Dermatitis exfoliative—Doxorubicin—bone cancer	6.13e-05	0.0013	CcSEcCtD
Methotrexate—ABCG2—bone marrow—bone cancer	6.09e-05	0.00469	CbGeAlD
Methotrexate—ABCG2—spinal cord—bone cancer	6.06e-05	0.00467	CbGeAlD
Methotrexate—Anaphylactic shock—Cisplatin—bone cancer	5.98e-05	0.00127	CcSEcCtD
Methotrexate—Anaphylactoid reaction—Doxorubicin—bone cancer	5.98e-05	0.00127	CcSEcCtD
Methotrexate—Infection—Cisplatin—bone cancer	5.94e-05	0.00126	CcSEcCtD
Methotrexate—Mood swings—Epirubicin—bone cancer	5.92e-05	0.00126	CcSEcCtD
Methotrexate—Cerebrovascular accident—Doxorubicin—bone cancer	5.9e-05	0.00126	CcSEcCtD
Methotrexate—Lethargy—Doxorubicin—bone cancer	5.9e-05	0.00126	CcSEcCtD
Methotrexate—Ataxia—Epirubicin—bone cancer	5.88e-05	0.00125	CcSEcCtD
Methotrexate—Nervous system disorder—Cisplatin—bone cancer	5.87e-05	0.00125	CcSEcCtD
Methotrexate—Thrombocytopenia—Cisplatin—bone cancer	5.86e-05	0.00125	CcSEcCtD
Methotrexate—Skin disorder—Cisplatin—bone cancer	5.81e-05	0.00124	CcSEcCtD
Methotrexate—Osteoarthritis—Doxorubicin—bone cancer	5.78e-05	0.00123	CcSEcCtD
Methotrexate—Hyperhidrosis—Cisplatin—bone cancer	5.78e-05	0.00123	CcSEcCtD
Methotrexate—Liver function test abnormal—Epirubicin—bone cancer	5.77e-05	0.00123	CcSEcCtD
Methotrexate—Anorexia—Cisplatin—bone cancer	5.7e-05	0.00121	CcSEcCtD
Methotrexate—Breast disorder—Epirubicin—bone cancer	5.65e-05	0.0012	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Epirubicin—bone cancer	5.63e-05	0.0012	CcSEcCtD
Methotrexate—Hypotension—Cisplatin—bone cancer	5.59e-05	0.00119	CcSEcCtD
Methotrexate—Mood swings—Doxorubicin—bone cancer	5.48e-05	0.00117	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Cisplatin—bone cancer	5.45e-05	0.00116	CcSEcCtD
Methotrexate—Ataxia—Doxorubicin—bone cancer	5.44e-05	0.00116	CcSEcCtD
Methotrexate—Asthma—Epirubicin—bone cancer	5.4e-05	0.00115	CcSEcCtD
Methotrexate—Paraesthesia—Cisplatin—bone cancer	5.37e-05	0.00114	CcSEcCtD
Methotrexate—Eosinophilia—Epirubicin—bone cancer	5.35e-05	0.00114	CcSEcCtD
Methotrexate—Liver function test abnormal—Doxorubicin—bone cancer	5.34e-05	0.00114	CcSEcCtD
Methotrexate—Dyspnoea—Cisplatin—bone cancer	5.33e-05	0.00113	CcSEcCtD
Methotrexate—Pancreatitis—Epirubicin—bone cancer	5.3e-05	0.00113	CcSEcCtD
Methotrexate—Breast disorder—Doxorubicin—bone cancer	5.23e-05	0.00111	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Doxorubicin—bone cancer	5.21e-05	0.00111	CcSEcCtD
Methotrexate—Decreased appetite—Cisplatin—bone cancer	5.2e-05	0.00111	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Cisplatin—bone cancer	5.16e-05	0.0011	CcSEcCtD
Methotrexate—Pancytopenia—Epirubicin—bone cancer	5.13e-05	0.00109	CcSEcCtD
Methotrexate—Pain—Cisplatin—bone cancer	5.12e-05	0.00109	CcSEcCtD
Methotrexate—Dysuria—Epirubicin—bone cancer	5.05e-05	0.00107	CcSEcCtD
Methotrexate—Neutropenia—Epirubicin—bone cancer	5.05e-05	0.00107	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Epirubicin—bone cancer	5.02e-05	0.00107	CcSEcCtD
Methotrexate—Asthma—Doxorubicin—bone cancer	5e-05	0.00106	CcSEcCtD
Methotrexate—Eosinophilia—Doxorubicin—bone cancer	4.95e-05	0.00105	CcSEcCtD
Methotrexate—Photosensitivity reaction—Epirubicin—bone cancer	4.93e-05	0.00105	CcSEcCtD
Methotrexate—Feeling abnormal—Cisplatin—bone cancer	4.93e-05	0.00105	CcSEcCtD
Methotrexate—Pancreatitis—Doxorubicin—bone cancer	4.9e-05	0.00104	CcSEcCtD
Methotrexate—Pneumonia—Epirubicin—bone cancer	4.84e-05	0.00103	CcSEcCtD
Methotrexate—Drowsiness—Epirubicin—bone cancer	4.82e-05	0.00102	CcSEcCtD
Methotrexate—Infestation—Epirubicin—bone cancer	4.82e-05	0.00102	CcSEcCtD
Methotrexate—Infestation NOS—Epirubicin—bone cancer	4.82e-05	0.00102	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Epirubicin—bone cancer	4.78e-05	0.00102	CcSEcCtD
Methotrexate—Pancytopenia—Doxorubicin—bone cancer	4.75e-05	0.00101	CcSEcCtD
Methotrexate—Renal failure—Epirubicin—bone cancer	4.73e-05	0.00101	CcSEcCtD
Methotrexate—Body temperature increased—Cisplatin—bone cancer	4.73e-05	0.00101	CcSEcCtD
Methotrexate—Stomatitis—Epirubicin—bone cancer	4.7e-05	0.000999	CcSEcCtD
Methotrexate—Conjunctivitis—Epirubicin—bone cancer	4.68e-05	0.000996	CcSEcCtD
Methotrexate—Dysuria—Doxorubicin—bone cancer	4.67e-05	0.000994	CcSEcCtD
Methotrexate—Neutropenia—Doxorubicin—bone cancer	4.67e-05	0.000994	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Doxorubicin—bone cancer	4.65e-05	0.000988	CcSEcCtD
Methotrexate—Sweating—Epirubicin—bone cancer	4.62e-05	0.000982	CcSEcCtD
Methotrexate—Haematuria—Epirubicin—bone cancer	4.59e-05	0.000977	CcSEcCtD
Methotrexate—Photosensitivity reaction—Doxorubicin—bone cancer	4.56e-05	0.000971	CcSEcCtD
Methotrexate—Hepatobiliary disease—Epirubicin—bone cancer	4.56e-05	0.000969	CcSEcCtD
Methotrexate—Epistaxis—Epirubicin—bone cancer	4.54e-05	0.000967	CcSEcCtD
Methotrexate—Agranulocytosis—Epirubicin—bone cancer	4.5e-05	0.000956	CcSEcCtD
Methotrexate—Pneumonia—Doxorubicin—bone cancer	4.48e-05	0.000954	CcSEcCtD
Methotrexate—Drowsiness—Doxorubicin—bone cancer	4.46e-05	0.000948	CcSEcCtD
Methotrexate—Infestation NOS—Doxorubicin—bone cancer	4.46e-05	0.000948	CcSEcCtD
Methotrexate—Infestation—Doxorubicin—bone cancer	4.46e-05	0.000948	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Doxorubicin—bone cancer	4.42e-05	0.00094	CcSEcCtD
Methotrexate—Hypersensitivity—Cisplatin—bone cancer	4.41e-05	0.000938	CcSEcCtD
Methotrexate—Renal failure—Doxorubicin—bone cancer	4.38e-05	0.000932	CcSEcCtD
Methotrexate—Haemoglobin—Epirubicin—bone cancer	4.35e-05	0.000925	CcSEcCtD
Methotrexate—Stomatitis—Doxorubicin—bone cancer	4.34e-05	0.000924	CcSEcCtD
Methotrexate—Conjunctivitis—Doxorubicin—bone cancer	4.33e-05	0.000922	CcSEcCtD
Methotrexate—Haemorrhage—Epirubicin—bone cancer	4.32e-05	0.00092	CcSEcCtD
Methotrexate—Hepatitis—Epirubicin—bone cancer	4.32e-05	0.00092	CcSEcCtD
Methotrexate—Asthenia—Cisplatin—bone cancer	4.29e-05	0.000913	CcSEcCtD
Methotrexate—Pharyngitis—Epirubicin—bone cancer	4.29e-05	0.000913	CcSEcCtD
Methotrexate—Sweating—Doxorubicin—bone cancer	4.27e-05	0.000909	CcSEcCtD
Methotrexate—Urinary tract disorder—Epirubicin—bone cancer	4.27e-05	0.000909	CcSEcCtD
Methotrexate—Haematuria—Doxorubicin—bone cancer	4.25e-05	0.000904	CcSEcCtD
Methotrexate—Urethral disorder—Epirubicin—bone cancer	4.24e-05	0.000902	CcSEcCtD
Methotrexate—Hepatobiliary disease—Doxorubicin—bone cancer	4.22e-05	0.000897	CcSEcCtD
Methotrexate—Epistaxis—Doxorubicin—bone cancer	4.2e-05	0.000894	CcSEcCtD
Methotrexate—Visual impairment—Epirubicin—bone cancer	4.17e-05	0.000887	CcSEcCtD
Methotrexate—Agranulocytosis—Doxorubicin—bone cancer	4.16e-05	0.000885	CcSEcCtD
Methotrexate—Diarrhoea—Cisplatin—bone cancer	4.09e-05	0.000871	CcSEcCtD
Methotrexate—Erythema multiforme—Epirubicin—bone cancer	4.09e-05	0.00087	CcSEcCtD
Methotrexate—Eye disorder—Epirubicin—bone cancer	4.04e-05	0.00086	CcSEcCtD
Methotrexate—Tinnitus—Epirubicin—bone cancer	4.03e-05	0.000858	CcSEcCtD
Methotrexate—Haemoglobin—Doxorubicin—bone cancer	4.02e-05	0.000856	CcSEcCtD
Methotrexate—Cardiac disorder—Epirubicin—bone cancer	4.01e-05	0.000854	CcSEcCtD
Methotrexate—Haemorrhage—Doxorubicin—bone cancer	4e-05	0.000851	CcSEcCtD
Methotrexate—Hepatitis—Doxorubicin—bone cancer	4e-05	0.000851	CcSEcCtD
Methotrexate—Pharyngitis—Doxorubicin—bone cancer	3.97e-05	0.000845	CcSEcCtD
Methotrexate—Urinary tract disorder—Doxorubicin—bone cancer	3.95e-05	0.000841	CcSEcCtD
Methotrexate—Angiopathy—Epirubicin—bone cancer	3.92e-05	0.000835	CcSEcCtD
Methotrexate—Urethral disorder—Doxorubicin—bone cancer	3.92e-05	0.000834	CcSEcCtD
Methotrexate—Immune system disorder—Epirubicin—bone cancer	3.91e-05	0.000831	CcSEcCtD
Methotrexate—Mediastinal disorder—Epirubicin—bone cancer	3.9e-05	0.000829	CcSEcCtD
Methotrexate—Chills—Epirubicin—bone cancer	3.88e-05	0.000825	CcSEcCtD
Methotrexate—Visual impairment—Doxorubicin—bone cancer	3.86e-05	0.00082	CcSEcCtD
Methotrexate—Alopecia—Epirubicin—bone cancer	3.82e-05	0.000813	CcSEcCtD
Methotrexate—Vomiting—Cisplatin—bone cancer	3.8e-05	0.000809	CcSEcCtD
Methotrexate—Mental disorder—Epirubicin—bone cancer	3.79e-05	0.000806	CcSEcCtD
Methotrexate—Erythema multiforme—Doxorubicin—bone cancer	3.78e-05	0.000805	CcSEcCtD
Methotrexate—Rash—Cisplatin—bone cancer	3.77e-05	0.000802	CcSEcCtD
Methotrexate—Dermatitis—Cisplatin—bone cancer	3.77e-05	0.000802	CcSEcCtD
Methotrexate—Erythema—Epirubicin—bone cancer	3.76e-05	0.000801	CcSEcCtD
Methotrexate—Malnutrition—Epirubicin—bone cancer	3.76e-05	0.000801	CcSEcCtD
Methotrexate—Eye disorder—Doxorubicin—bone cancer	3.74e-05	0.000795	CcSEcCtD
Methotrexate—Tinnitus—Doxorubicin—bone cancer	3.73e-05	0.000794	CcSEcCtD
Methotrexate—Cardiac disorder—Doxorubicin—bone cancer	3.71e-05	0.00079	CcSEcCtD
Methotrexate—Dysgeusia—Epirubicin—bone cancer	3.69e-05	0.000784	CcSEcCtD
Methotrexate—Back pain—Epirubicin—bone cancer	3.64e-05	0.000775	CcSEcCtD
Methotrexate—Angiopathy—Doxorubicin—bone cancer	3.63e-05	0.000772	CcSEcCtD
Methotrexate—Immune system disorder—Doxorubicin—bone cancer	3.61e-05	0.000769	CcSEcCtD
Methotrexate—Mediastinal disorder—Doxorubicin—bone cancer	3.61e-05	0.000767	CcSEcCtD
Methotrexate—Chills—Doxorubicin—bone cancer	3.59e-05	0.000764	CcSEcCtD
Methotrexate—Nausea—Cisplatin—bone cancer	3.55e-05	0.000756	CcSEcCtD
Methotrexate—Vision blurred—Epirubicin—bone cancer	3.55e-05	0.000755	CcSEcCtD
Methotrexate—Alopecia—Doxorubicin—bone cancer	3.54e-05	0.000752	CcSEcCtD
Methotrexate—Mental disorder—Doxorubicin—bone cancer	3.51e-05	0.000746	CcSEcCtD
Methotrexate—Ill-defined disorder—Epirubicin—bone cancer	3.49e-05	0.000743	CcSEcCtD
Methotrexate—Erythema—Doxorubicin—bone cancer	3.48e-05	0.000741	CcSEcCtD
Methotrexate—Malnutrition—Doxorubicin—bone cancer	3.48e-05	0.000741	CcSEcCtD
Methotrexate—Anaemia—Epirubicin—bone cancer	3.48e-05	0.00074	CcSEcCtD
Methotrexate—Dysgeusia—Doxorubicin—bone cancer	3.41e-05	0.000726	CcSEcCtD
Methotrexate—Malaise—Epirubicin—bone cancer	3.39e-05	0.000722	CcSEcCtD
Methotrexate—Vertigo—Epirubicin—bone cancer	3.38e-05	0.00072	CcSEcCtD
Methotrexate—Leukopenia—Epirubicin—bone cancer	3.37e-05	0.000717	CcSEcCtD
Methotrexate—Back pain—Doxorubicin—bone cancer	3.37e-05	0.000717	CcSEcCtD
Methotrexate—Cough—Epirubicin—bone cancer	3.28e-05	0.000699	CcSEcCtD
Methotrexate—Vision blurred—Doxorubicin—bone cancer	3.28e-05	0.000698	CcSEcCtD
Methotrexate—Convulsion—Epirubicin—bone cancer	3.26e-05	0.000694	CcSEcCtD
Methotrexate—Ill-defined disorder—Doxorubicin—bone cancer	3.23e-05	0.000688	CcSEcCtD
Methotrexate—Anaemia—Doxorubicin—bone cancer	3.22e-05	0.000685	CcSEcCtD
Methotrexate—Arthralgia—Epirubicin—bone cancer	3.2e-05	0.000682	CcSEcCtD
Methotrexate—Myalgia—Epirubicin—bone cancer	3.2e-05	0.000682	CcSEcCtD
Methotrexate—Chest pain—Epirubicin—bone cancer	3.2e-05	0.000682	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	3.18e-05	0.000677	CcSEcCtD
Methotrexate—Discomfort—Epirubicin—bone cancer	3.17e-05	0.000674	CcSEcCtD
Methotrexate—Malaise—Doxorubicin—bone cancer	3.14e-05	0.000668	CcSEcCtD
Methotrexate—Vertigo—Doxorubicin—bone cancer	3.13e-05	0.000666	CcSEcCtD
Methotrexate—Leukopenia—Doxorubicin—bone cancer	3.12e-05	0.000663	CcSEcCtD
Methotrexate—Confusional state—Epirubicin—bone cancer	3.1e-05	0.000659	CcSEcCtD
Methotrexate—Anaphylactic shock—Epirubicin—bone cancer	3.07e-05	0.000654	CcSEcCtD
Methotrexate—Infection—Epirubicin—bone cancer	3.05e-05	0.000649	CcSEcCtD
Methotrexate—Cough—Doxorubicin—bone cancer	3.04e-05	0.000647	CcSEcCtD
Methotrexate—Convulsion—Doxorubicin—bone cancer	3.02e-05	0.000642	CcSEcCtD
Methotrexate—Nervous system disorder—Epirubicin—bone cancer	3.01e-05	0.000641	CcSEcCtD
Methotrexate—Thrombocytopenia—Epirubicin—bone cancer	3.01e-05	0.00064	CcSEcCtD
Methotrexate—ABCB1—bone marrow—bone cancer	3e-05	0.00231	CbGeAlD
Methotrexate—ABCB1—spinal cord—bone cancer	2.99e-05	0.0023	CbGeAlD
Methotrexate—Skin disorder—Epirubicin—bone cancer	2.98e-05	0.000635	CcSEcCtD
Methotrexate—Hyperhidrosis—Epirubicin—bone cancer	2.97e-05	0.000632	CcSEcCtD
Methotrexate—Arthralgia—Doxorubicin—bone cancer	2.97e-05	0.000631	CcSEcCtD
Methotrexate—Chest pain—Doxorubicin—bone cancer	2.97e-05	0.000631	CcSEcCtD
Methotrexate—Myalgia—Doxorubicin—bone cancer	2.97e-05	0.000631	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	2.94e-05	0.000627	CcSEcCtD
Methotrexate—Discomfort—Doxorubicin—bone cancer	2.93e-05	0.000623	CcSEcCtD
Methotrexate—Anorexia—Epirubicin—bone cancer	2.93e-05	0.000623	CcSEcCtD
Methotrexate—Hypotension—Epirubicin—bone cancer	2.87e-05	0.000611	CcSEcCtD
Methotrexate—Confusional state—Doxorubicin—bone cancer	2.87e-05	0.00061	CcSEcCtD
Methotrexate—Anaphylactic shock—Doxorubicin—bone cancer	2.84e-05	0.000605	CcSEcCtD
Methotrexate—Infection—Doxorubicin—bone cancer	2.82e-05	0.000601	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Epirubicin—bone cancer	2.8e-05	0.000595	CcSEcCtD
Methotrexate—Nervous system disorder—Doxorubicin—bone cancer	2.79e-05	0.000593	CcSEcCtD
Methotrexate—Thrombocytopenia—Doxorubicin—bone cancer	2.78e-05	0.000592	CcSEcCtD
Methotrexate—Insomnia—Epirubicin—bone cancer	2.78e-05	0.000591	CcSEcCtD
Methotrexate—Skin disorder—Doxorubicin—bone cancer	2.76e-05	0.000587	CcSEcCtD
Methotrexate—Paraesthesia—Epirubicin—bone cancer	2.76e-05	0.000587	CcSEcCtD
Methotrexate—Hyperhidrosis—Doxorubicin—bone cancer	2.75e-05	0.000585	CcSEcCtD
Methotrexate—Dyspnoea—Epirubicin—bone cancer	2.74e-05	0.000583	CcSEcCtD
Methotrexate—Somnolence—Epirubicin—bone cancer	2.73e-05	0.000581	CcSEcCtD
Methotrexate—Anorexia—Doxorubicin—bone cancer	2.71e-05	0.000576	CcSEcCtD
Methotrexate—Dyspepsia—Epirubicin—bone cancer	2.7e-05	0.000575	CcSEcCtD
Methotrexate—Decreased appetite—Epirubicin—bone cancer	2.67e-05	0.000568	CcSEcCtD
Methotrexate—Hypotension—Doxorubicin—bone cancer	2.66e-05	0.000565	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Epirubicin—bone cancer	2.65e-05	0.000564	CcSEcCtD
Methotrexate—Fatigue—Epirubicin—bone cancer	2.65e-05	0.000564	CcSEcCtD
Methotrexate—Pain—Epirubicin—bone cancer	2.63e-05	0.000559	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Doxorubicin—bone cancer	2.59e-05	0.000551	CcSEcCtD
Methotrexate—Insomnia—Doxorubicin—bone cancer	2.57e-05	0.000547	CcSEcCtD
Methotrexate—Paraesthesia—Doxorubicin—bone cancer	2.55e-05	0.000543	CcSEcCtD
Methotrexate—Dyspnoea—Doxorubicin—bone cancer	2.53e-05	0.000539	CcSEcCtD
Methotrexate—Feeling abnormal—Epirubicin—bone cancer	2.53e-05	0.000539	CcSEcCtD
Methotrexate—Somnolence—Doxorubicin—bone cancer	2.53e-05	0.000538	CcSEcCtD
Methotrexate—Gastrointestinal pain—Epirubicin—bone cancer	2.51e-05	0.000534	CcSEcCtD
Methotrexate—Dyspepsia—Doxorubicin—bone cancer	2.5e-05	0.000532	CcSEcCtD
Methotrexate—ABCC4—Transmembrane transport of small molecules—TUBB2A—bone cancer	2.5e-05	0.000652	CbGpPWpGaD
Methotrexate—Decreased appetite—Doxorubicin—bone cancer	2.47e-05	0.000526	CcSEcCtD
Methotrexate—PGD—Disease—ENO2—bone cancer	2.46e-05	0.000643	CbGpPWpGaD
Methotrexate—Gastrointestinal disorder—Doxorubicin—bone cancer	2.45e-05	0.000522	CcSEcCtD
Methotrexate—Fatigue—Doxorubicin—bone cancer	2.45e-05	0.000521	CcSEcCtD
Methotrexate—Urticaria—Epirubicin—bone cancer	2.44e-05	0.000519	CcSEcCtD
Methotrexate—ABCC2—Transmembrane transport of small molecules—TUBB4B—bone cancer	2.44e-05	0.000637	CbGpPWpGaD
Methotrexate—Pain—Doxorubicin—bone cancer	2.43e-05	0.000517	CcSEcCtD
Methotrexate—Body temperature increased—Epirubicin—bone cancer	2.43e-05	0.000517	CcSEcCtD
Methotrexate—Abdominal pain—Epirubicin—bone cancer	2.43e-05	0.000517	CcSEcCtD
Methotrexate—ABCC1—Transmembrane transport of small molecules—TUBB4B—bone cancer	2.41e-05	0.00063	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—NT5C3A—bone cancer	2.41e-05	0.000629	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—NDUFA12—bone cancer	2.41e-05	0.000628	CbGpPWpGaD
Methotrexate—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	2.4e-05	0.000628	CbGpPWpGaD
Methotrexate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	2.38e-05	0.000623	CbGpPWpGaD
Methotrexate—ABCG2—HIF-1-alpha transcription factor network—JUN—bone cancer	2.38e-05	0.000621	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—GNA11—bone cancer	2.35e-05	0.000615	CbGpPWpGaD
Methotrexate—Feeling abnormal—Doxorubicin—bone cancer	2.34e-05	0.000498	CcSEcCtD
Methotrexate—Gastrointestinal pain—Doxorubicin—bone cancer	2.32e-05	0.000495	CcSEcCtD
Methotrexate—FPGS—Disease—TGFBR2—bone cancer	2.32e-05	0.000607	CbGpPWpGaD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	2.31e-05	0.000604	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	2.29e-05	0.000598	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—GSTP1—bone cancer	2.29e-05	0.000598	CbGpPWpGaD
Methotrexate—PGD—Disease—DHFR—bone cancer	2.28e-05	0.000597	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—DHFR—bone cancer	2.28e-05	0.000595	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—CYP3A4—bone cancer	2.27e-05	0.000594	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—CYP3A4—bone cancer	2.27e-05	0.000594	CbGpPWpGaD
Methotrexate—Hypersensitivity—Epirubicin—bone cancer	2.26e-05	0.000482	CcSEcCtD
Methotrexate—Urticaria—Doxorubicin—bone cancer	2.26e-05	0.00048	CcSEcCtD
Methotrexate—SLC46A1—Metabolism—ENO2—bone cancer	2.25e-05	0.000589	CbGpPWpGaD
Methotrexate—Body temperature increased—Doxorubicin—bone cancer	2.25e-05	0.000478	CcSEcCtD
Methotrexate—Abdominal pain—Doxorubicin—bone cancer	2.25e-05	0.000478	CcSEcCtD
Methotrexate—SLCO1B3—Metabolism—NT5C3A—bone cancer	2.21e-05	0.000577	CbGpPWpGaD
Methotrexate—TYMS—Retinoblastoma (RB) in Cancer—TP53—bone cancer	2.21e-05	0.000576	CbGpPWpGaD
Methotrexate—Asthenia—Epirubicin—bone cancer	2.2e-05	0.000469	CcSEcCtD
Methotrexate—DHFR—Cell Cycle—CHEK2—bone cancer	2.18e-05	0.00057	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—TUBB2A—bone cancer	2.17e-05	0.000568	CbGpPWpGaD
Methotrexate—Pruritus—Epirubicin—bone cancer	2.17e-05	0.000462	CcSEcCtD
Methotrexate—SLC16A1—Hemostasis—IL3—bone cancer	2.13e-05	0.000557	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	2.12e-05	0.000554	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—TUBB2A—bone cancer	2.11e-05	0.00055	CbGpPWpGaD
Methotrexate—Diarrhoea—Epirubicin—bone cancer	2.1e-05	0.000447	CcSEcCtD
Methotrexate—SLCO1A2—Metabolism—NDUFA12—bone cancer	2.09e-05	0.000547	CbGpPWpGaD
Methotrexate—Hypersensitivity—Doxorubicin—bone cancer	2.09e-05	0.000446	CcSEcCtD
Methotrexate—SLC46A1—Metabolism—DHFR—bone cancer	2.09e-05	0.000546	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—TUBB2A—bone cancer	2.08e-05	0.000544	CbGpPWpGaD
Methotrexate—PGD—Metabolism—ENO2—bone cancer	2.06e-05	0.000539	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.05e-05	0.000535	CbGpPWpGaD
Methotrexate—Asthenia—Doxorubicin—bone cancer	2.04e-05	0.000434	CcSEcCtD
Methotrexate—Dizziness—Epirubicin—bone cancer	2.03e-05	0.000432	CcSEcCtD
Methotrexate—Pruritus—Doxorubicin—bone cancer	2.01e-05	0.000428	CcSEcCtD
Methotrexate—ABCC3—Metabolism—NT5C3A—bone cancer	1.99e-05	0.000521	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	1.98e-05	0.000517	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	1.98e-05	0.000516	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—GNA11—bone cancer	1.95e-05	0.000511	CbGpPWpGaD
Methotrexate—Vomiting—Epirubicin—bone cancer	1.95e-05	0.000416	CcSEcCtD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	1.95e-05	0.00051	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—GSTP1—bone cancer	1.95e-05	0.000508	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—GSTP1—bone cancer	1.95e-05	0.000508	CbGpPWpGaD
Methotrexate—Diarrhoea—Doxorubicin—bone cancer	1.94e-05	0.000414	CcSEcCtD
Methotrexate—Rash—Epirubicin—bone cancer	1.94e-05	0.000412	CcSEcCtD
Methotrexate—Dermatitis—Epirubicin—bone cancer	1.94e-05	0.000412	CcSEcCtD
Methotrexate—Headache—Epirubicin—bone cancer	1.92e-05	0.000409	CcSEcCtD
Methotrexate—ABCC4—Hemostasis—SPARC—bone cancer	1.92e-05	0.000501	CbGpPWpGaD
Methotrexate—PGD—Metabolism—DHFR—bone cancer	1.91e-05	0.0005	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—CHEK2—bone cancer	1.9e-05	0.000497	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—NDUFA12—bone cancer	1.89e-05	0.000492	CbGpPWpGaD
Methotrexate—Dizziness—Doxorubicin—bone cancer	1.88e-05	0.0004	CcSEcCtD
Methotrexate—SLC19A1—Disease—KIT—bone cancer	1.86e-05	0.000487	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—BRCA2—bone cancer	1.85e-05	0.000483	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	1.83e-05	0.000478	CbGpPWpGaD
Methotrexate—Nausea—Epirubicin—bone cancer	1.82e-05	0.000388	CcSEcCtD
Methotrexate—SLC46A1—Disease—TGFBR2—bone cancer	1.81e-05	0.000473	CbGpPWpGaD
Methotrexate—Vomiting—Doxorubicin—bone cancer	1.81e-05	0.000385	CcSEcCtD
Methotrexate—Rash—Doxorubicin—bone cancer	1.79e-05	0.000381	CcSEcCtD
Methotrexate—SLCO1B1—Metabolism—NDUFA12—bone cancer	1.79e-05	0.000468	CbGpPWpGaD
Methotrexate—Dermatitis—Doxorubicin—bone cancer	1.79e-05	0.000381	CcSEcCtD
Methotrexate—PGD—Metabolism—GNA11—bone cancer	1.79e-05	0.000467	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.78e-05	0.000465	CbGpPWpGaD
Methotrexate—Headache—Doxorubicin—bone cancer	1.78e-05	0.000379	CcSEcCtD
Methotrexate—SLC46A1—Metabolism—CYP3A4—bone cancer	1.77e-05	0.000463	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—GNA11—bone cancer	1.76e-05	0.000458	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—BRAF—bone cancer	1.75e-05	0.000458	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—NT5C3A—bone cancer	1.74e-05	0.000453	CbGpPWpGaD
Methotrexate—TYMS—Circadian rythm related genes—JUN—bone cancer	1.71e-05	0.000447	CbGpPWpGaD
Methotrexate—Nausea—Doxorubicin—bone cancer	1.69e-05	0.000359	CcSEcCtD
Methotrexate—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	1.69e-05	0.00044	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	1.66e-05	0.000433	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—NDUFA12—bone cancer	1.66e-05	0.000433	CbGpPWpGaD
Methotrexate—PGD—Disease—TGFBR2—bone cancer	1.66e-05	0.000432	CbGpPWpGaD
Methotrexate—MTHFR—Disease—ENO2—bone cancer	1.62e-05	0.000424	CbGpPWpGaD
Methotrexate—PGD—Metabolism—CYP3A4—bone cancer	1.62e-05	0.000423	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—BRCA2—bone cancer	1.61e-05	0.000421	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—IL3—bone cancer	1.59e-05	0.000416	CbGpPWpGaD
Methotrexate—AOX1—Disease—ENO2—bone cancer	1.59e-05	0.000414	CbGpPWpGaD
Methotrexate—FPGS—Disease—KIT—bone cancer	1.59e-05	0.000414	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—NT5C3A—bone cancer	1.56e-05	0.000408	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	1.54e-05	0.000402	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—CDK4—bone cancer	1.53e-05	0.000401	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—GSTP1—bone cancer	1.52e-05	0.000396	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	1.51e-05	0.000395	CbGpPWpGaD
Methotrexate—MTHFR—Disease—DHFR—bone cancer	1.51e-05	0.000394	CbGpPWpGaD
Methotrexate—FPGS—Disease—BRAF—bone cancer	1.49e-05	0.000389	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—NT5C3A—bone cancer	1.48e-05	0.000388	CbGpPWpGaD
Methotrexate—AOX1—Disease—DHFR—bone cancer	1.47e-05	0.000384	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—MDM2—bone cancer	1.47e-05	0.000383	CbGpPWpGaD
Methotrexate—DHFR—Disease—ENO2—bone cancer	1.44e-05	0.000377	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—PTGS2—bone cancer	1.42e-05	0.00037	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.4e-05	0.000366	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—PLAU—bone cancer	1.4e-05	0.000366	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	1.4e-05	0.000365	CbGpPWpGaD
Methotrexate—PGD—Metabolism—GSTP1—bone cancer	1.39e-05	0.000362	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	1.38e-05	0.000359	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—NT5C3A—bone cancer	1.37e-05	0.000359	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—CDK4—bone cancer	1.37e-05	0.000358	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—ENO2—bone cancer	1.36e-05	0.000355	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	1.36e-05	0.000354	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—CDK4—bone cancer	1.34e-05	0.000349	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—RB1—bone cancer	1.33e-05	0.000348	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—ENO2—bone cancer	1.33e-05	0.000347	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	1.31e-05	0.000342	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	1.29e-05	0.000338	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	1.29e-05	0.000336	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—DHFR—bone cancer	1.26e-05	0.00033	CbGpPWpGaD
Methotrexate—FPGS—Disease—MDM2—bone cancer	1.25e-05	0.000326	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—KIT—bone cancer	1.24e-05	0.000323	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—DHFR—bone cancer	1.23e-05	0.000322	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—ENO2—bone cancer	1.21e-05	0.000316	CbGpPWpGaD
Methotrexate—FPGS—Disease—PTGS2—bone cancer	1.2e-05	0.000314	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—CDK4—bone cancer	1.2e-05	0.000312	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—RB1—bone cancer	1.19e-05	0.000311	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—PTGS2—bone cancer	1.19e-05	0.00031	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—GNA11—bone cancer	1.18e-05	0.000308	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.18e-05	0.000307	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—RB1—bone cancer	1.16e-05	0.000304	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—BRAF—bone cancer	1.16e-05	0.000303	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—GNA11—bone cancer	1.15e-05	0.000301	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	1.15e-05	0.0003	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	1.15e-05	0.0003	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	1.13e-05	0.000295	CbGpPWpGaD
Methotrexate—PGD—Disease—KIT—bone cancer	1.13e-05	0.000295	CbGpPWpGaD
Methotrexate—TYMS—Circadian rythm related genes—TP53—bone cancer	1.13e-05	0.000295	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—ENO2—bone cancer	1.1e-05	0.000288	CbGpPWpGaD
Methotrexate—MTHFR—Disease—TGFBR2—bone cancer	1.09e-05	0.000285	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—CYP3A4—bone cancer	1.07e-05	0.000279	CbGpPWpGaD
Methotrexate—AOX1—Disease—TGFBR2—bone cancer	1.07e-05	0.000279	CbGpPWpGaD
Methotrexate—PGD—Disease—BRAF—bone cancer	1.06e-05	0.000277	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—ENO2—bone cancer	1.05e-05	0.000275	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—GNA11—bone cancer	1.05e-05	0.000274	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—CYP3A4—bone cancer	1.04e-05	0.000273	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—PLAU—bone cancer	1.04e-05	0.000273	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—RB1—bone cancer	1.04e-05	0.000272	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NDUFA12—bone cancer	1.02e-05	0.000267	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—DHFR—bone cancer	1.02e-05	0.000267	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—MDM2—bone cancer	1.02e-05	0.000265	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—PTGS2—bone cancer	1.01e-05	0.000263	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—PTGS2—bone cancer	1.01e-05	0.000263	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—EGFR—bone cancer	1e-05	0.000262	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	9.9e-06	0.000259	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—DHFR—bone cancer	9.79e-06	0.000256	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—MDM2—bone cancer	9.73e-06	0.000254	CbGpPWpGaD
Methotrexate—DHFR—Disease—TGFBR2—bone cancer	9.7e-06	0.000253	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—TP53—bone cancer	9.69e-06	0.000253	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ENO2—bone cancer	9.68e-06	0.000253	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—GNA11—bone cancer	9.55e-06	0.000249	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—CYP3A4—bone cancer	9.5e-06	0.000248	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—PTGS2—bone cancer	9.38e-06	0.000245	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—GSTP1—bone cancer	9.15e-06	0.000239	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—GNA11—bone cancer	9.15e-06	0.000239	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—DHFR—bone cancer	8.98e-06	0.000234	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NDUFA12—bone cancer	8.97e-06	0.000234	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—GSTP1—bone cancer	8.93e-06	0.000233	CbGpPWpGaD
Methotrexate—PGD—Disease—MDM2—bone cancer	8.9e-06	0.000232	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—MDM2—bone cancer	8.87e-06	0.000232	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ENO2—bone cancer	8.73e-06	0.000228	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—SPARC—bone cancer	8.69e-06	0.000227	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—CYP3A4—bone cancer	8.66e-06	0.000226	CbGpPWpGaD
Methotrexate—PGD—Disease—PTGS2—bone cancer	8.58e-06	0.000224	CbGpPWpGaD
Methotrexate—FPGS—Disease—EGFR—bone cancer	8.53e-06	0.000223	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	8.53e-06	0.000223	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NT5C3A—bone cancer	8.48e-06	0.000221	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—GNA11—bone cancer	8.39e-06	0.000219	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—CYP3A4—bone cancer	8.29e-06	0.000217	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ENO2—bone cancer	8.17e-06	0.000213	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—GSTP1—bone cancer	8.13e-06	0.000212	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—DHFR—bone cancer	8.1e-06	0.000212	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—GNA11—bone cancer	7.94e-06	0.000207	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PTGS2—bone cancer	7.85e-06	0.000205	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—CYP3A4—bone cancer	7.61e-06	0.000199	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ENO2—bone cancer	7.6e-06	0.000199	CbGpPWpGaD
Methotrexate—ABCC1—Disease—DHFR—bone cancer	7.58e-06	0.000198	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—GNA11—bone cancer	7.57e-06	0.000198	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	7.57e-06	0.000198	CbGpPWpGaD
Methotrexate—MTHFR—Disease—KIT—bone cancer	7.45e-06	0.000195	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NT5C3A—bone cancer	7.43e-06	0.000194	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—GSTP1—bone cancer	7.4e-06	0.000193	CbGpPWpGaD
Methotrexate—AOX1—Disease—KIT—bone cancer	7.28e-06	0.00019	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IL3—bone cancer	7.2e-06	0.000188	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PTGS2—bone cancer	7.18e-06	0.000188	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—GSTP1—bone cancer	7.09e-06	0.000185	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—DHFR—bone cancer	7.05e-06	0.000184	CbGpPWpGaD
Methotrexate—MTHFR—Disease—BRAF—bone cancer	7e-06	0.000183	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CYP3A4—bone cancer	6.86e-06	0.000179	CbGpPWpGaD
Methotrexate—AOX1—Disease—BRAF—bone cancer	6.84e-06	0.000179	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ENO2—bone cancer	6.84e-06	0.000179	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.83e-06	0.000178	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—EGFR—bone cancer	6.65e-06	0.000174	CbGpPWpGaD
Methotrexate—DHFR—Disease—KIT—bone cancer	6.62e-06	0.000173	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GNA11—bone cancer	6.59e-06	0.000172	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—GSTP1—bone cancer	6.51e-06	0.00017	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ENO2—bone cancer	6.5e-06	0.00017	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—DHFR—bone cancer	6.35e-06	0.000166	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	6.32e-06	0.000165	CbGpPWpGaD
Methotrexate—DHFR—Disease—BRAF—bone cancer	6.22e-06	0.000163	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	6.1e-06	0.000159	CbGpPWpGaD
Methotrexate—PGD—Disease—EGFR—bone cancer	6.08e-06	0.000159	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—DHFR—bone cancer	6.03e-06	0.000158	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ENO2—bone cancer	6.02e-06	0.000157	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CYP3A4—bone cancer	5.98e-06	0.000156	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.95e-06	0.000155	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GNA11—bone cancer	5.93e-06	0.000155	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—GSTP1—bone cancer	5.87e-06	0.000153	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MDM2—bone cancer	5.87e-06	0.000153	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—TP53—bone cancer	5.83e-06	0.000152	CbGpPWpGaD
Methotrexate—AOX1—Disease—MDM2—bone cancer	5.73e-06	0.00015	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PTGS2—bone cancer	5.66e-06	0.000148	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GNA11—bone cancer	5.64e-06	0.000147	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TP53—bone cancer	5.63e-06	0.000147	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—DHFR—bone cancer	5.59e-06	0.000146	CbGpPWpGaD
Methotrexate—AOX1—Disease—PTGS2—bone cancer	5.53e-06	0.000144	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	5.5e-06	0.000144	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TGFBR2—bone cancer	5.49e-06	0.000143	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CYP3A4—bone cancer	5.38e-06	0.00014	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.35e-06	0.00014	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GNA11—bone cancer	5.22e-06	0.000136	CbGpPWpGaD
Methotrexate—DHFR—Disease—MDM2—bone cancer	5.22e-06	0.000136	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GSTP1—bone cancer	5.11e-06	0.000133	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CYP3A4—bone cancer	5.11e-06	0.000133	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TP53—bone cancer	5.09e-06	0.000133	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.08e-06	0.000133	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTGS2—bone cancer	5.03e-06	0.000131	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTGS2—bone cancer	4.74e-06	0.000124	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP3A4—bone cancer	4.73e-06	0.000124	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PLAU—bone cancer	4.72e-06	0.000123	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTGS2—bone cancer	4.63e-06	0.000121	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GSTP1—bone cancer	4.6e-06	0.00012	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GSTP1—bone cancer	4.37e-06	0.000114	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	4.32e-06	0.000113	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTGS2—bone cancer	4.21e-06	0.00011	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—bone cancer	4.2e-06	0.00011	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GSTP1—bone cancer	4.05e-06	0.000106	CbGpPWpGaD
Methotrexate—MTHFR—Disease—EGFR—bone cancer	4.01e-06	0.000105	CbGpPWpGaD
Methotrexate—AOX1—Disease—EGFR—bone cancer	3.92e-06	0.000102	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTGS2—bone cancer	3.84e-06	0.0001	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KIT—bone cancer	3.75e-06	9.79e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ENO2—bone cancer	3.71e-06	9.7e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTGS2—bone cancer	3.67e-06	9.59e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.63e-06	9.47e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—EGFR—bone cancer	3.56e-06	9.31e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—BRAF—bone cancer	3.52e-06	9.2e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—DHFR—bone cancer	3.45e-06	9e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTGS2—bone cancer	3.37e-06	8.8e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ENO2—bone cancer	3.25e-06	8.5e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GNA11—bone cancer	3.22e-06	8.41e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTGS2—bone cancer	3.04e-06	7.94e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—DHFR—bone cancer	3.02e-06	7.89e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MDM2—bone cancer	2.95e-06	7.71e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP3A4—bone cancer	2.92e-06	7.63e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.91e-06	7.59e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTGS2—bone cancer	2.85e-06	7.43e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GNA11—bone cancer	2.82e-06	7.37e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTGS2—bone cancer	2.65e-06	6.92e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP3A4—bone cancer	2.56e-06	6.68e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTP1—bone cancer	2.5e-06	6.52e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTGS2—bone cancer	2.38e-06	6.22e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTGS2—bone cancer	2.26e-06	5.91e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTP1—bone cancer	2.19e-06	5.71e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTGS2—bone cancer	2.1e-06	5.48e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGFR—bone cancer	2.02e-06	5.27e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—bone cancer	1.9e-06	4.96e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS2—bone cancer	1.29e-06	3.38e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS2—bone cancer	1.13e-06	2.96e-05	CbGpPWpGaD
